Phase I-II Trial of Sunitinib Plus Nivolumab After Standard Treatment in Advanced Soft Tissue and Bone Sarcomas

Trial Profile

Phase I-II Trial of Sunitinib Plus Nivolumab After Standard Treatment in Advanced Soft Tissue and Bone Sarcomas

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 13 Sep 2017

At a glance

  • Drugs Nivolumab (Primary) ; Sunitinib (Primary)
  • Indications Alveolar soft part sarcoma; Bone cancer; Chondrosarcoma; Clear cell sarcoma; Ewing's sarcoma; Osteosarcoma; Soft tissue sarcoma; Synovial sarcoma
  • Focus Therapeutic Use
  • Acronyms ImmunoSarc
  • Most Recent Events

    • 24 May 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top